Single-Dose Epigenetic Therapy Enters Human Trials to Slash LDL Cholesterol
Scribe Therapeutics launches first human trial of STX-1150, a reversible epigenetic therapy targeting PCSK9 to lower LDL without altering DNA.
Summary
A biotech company called Scribe Therapeutics has received approval to test a new cholesterol-lowering treatment in humans for the first time. The therapy, STX-1150, uses a lipid nanoparticle to deliver genetic instructions into liver cells, silencing a gene called PCSK9 that controls LDL cholesterol levels. Unlike gene editing, this approach does not permanently change DNA — it works epigenetically, meaning it switches the gene off without rewriting it. The company says a single dose could produce long-lasting LDL reduction. Up to 64 adults with high cardiovascular risk will be enrolled across Australia and New Zealand, monitored for one year. This trial represents a potentially significant step toward durable, low-burden cardiovascular disease prevention.
Detailed Summary
High LDL cholesterol remains one of the most powerful and modifiable risk factors for cardiovascular disease, the leading cause of death globally. Current treatments like statins require daily dosing, and injectable PCSK9 inhibitors need repeat administration every few weeks. A one-time or infrequent epigenetic therapy could dramatically improve adherence and long-term outcomes for millions of people.
Scribe Therapeutics has received clearance from Australia's Therapeutic Goods Administration to begin a Phase 1 clinical trial of STX-1150, an investigational liver-targeted therapy. The treatment delivers mRNA encoding an engineered epigenetic silencer — called ELXR (Epigenetic Long-term X-Repressor) — along with a guide RNA, packaged inside a lipid nanoparticle. Once inside liver cells, it silences PCSK9, a protein that normally degrades LDL receptors. Blocking PCSK9 allows more LDL to be cleared from the bloodstream.
The key distinction from CRISPR-style gene editing is reversibility. ELXR suppresses gene activity through epigenetic mechanisms rather than cutting or rewriting DNA, which theoretically reduces permanent off-target risks. Scribe claims a single dose could sustain LDL lowering over the long term, though this has yet to be confirmed in humans.
The Phase 1 trial is open-label and dose-escalating, enrolling up to 64 adults with elevated LDL and increased cardiovascular risk. Sites in Australia and New Zealand will monitor participants for 12 months post-treatment. The lead site is Monash Health's Victorian Heart Hospital, with cardiologist Stephen Nicholls as principal investigator.
For longevity-focused individuals, this technology represents a frontier approach to one of the most evidence-backed targets in cardiovascular prevention. However, the trial is still in its earliest safety phase. Efficacy data, durability of effect, and long-term safety in humans remain unproven and will take years to establish.
Key Findings
- STX-1150 uses epigenetic silencing to suppress PCSK9 in liver cells, potentially lowering LDL after a single dose.
- Unlike CRISPR, the ELXR platform does not permanently alter DNA, offering a potentially reversible safety profile.
- Phase 1 trial enrolling up to 64 high-cardiovascular-risk adults across Australia and New Zealand, monitored for one year.
- Lipid nanoparticle delivery targets the liver directly, similar to technology used in mRNA COVID vaccines.
- If effective, a one-time LDL-lowering therapy could outperform daily statins and biweekly injections for adherence.
Methodology
This is a news report summarizing a regulatory clearance announcement from Scribe Therapeutics, not a peer-reviewed study. The source, Longevity.Technology, is a credible longevity-focused publication, but the claims originate from a company press release. No published clinical or peer-reviewed preclinical data is cited in the article.
Study Limitations
All efficacy and safety claims are preclinical or company-stated; no peer-reviewed human data exists yet. The trial is Phase 1, focused on safety and dosing — not designed to prove LDL-lowering efficacy. Long-term durability of epigenetic silencing and reversibility claims require independent verification in human studies.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.